Skip to content
Clinical Trials – home
BelgiumBack to Belgium

Clinical trials in Ottignies – page 103

1 888 clinical trials in Ottignies, Belgium across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

Ottignies at a glance
1 888
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

1 888 trials in Ottignies

Open in trial search

Study on the Effects and Safety of Efgartigimod PH20 SC for Adults with Active Idiopathic Inflammatory Myopathy

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Efgartigimod Alfa
  • Sponsor:Argenx

Neoplasm+2

Not recruiting

Study of ELVN-002 with Trastuzumab and Chemotherapy for Patients with Advanced HER2+ Solid Tumors, Colorectal Cancer, and Breast Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Enliven Therapeutics Inc.

K-ras gene mutation+2

Not recruiting

Study Comparing Divarasib, Sotorasib, and Adagrasib for Patients with Advanced or Metastatic KRAS G12C-Positive Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Sponsor:F. Hoffmann-La Roche AG

Study Comparing Epcoritamab and Lenalidomide with a Drug Combination for Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Epcoritamab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Study of Latozinemab for Patients with Neurodegenerative Diseases Who Previously Participated in a Latozinemab Study

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Latozinemab
  • Sponsor:Alector LLC

Breast cancer+7

Not recruiting

Study of sacituzumab govitecan compared to standard therapy in HER2-negative breast cancer patients with high risk of relapse after neoadjuvant treatment

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:GBG Forschungs GmbH

Study of emactuzumab compared to placebo in patients with tenosynovial giant cell tumor

Investigational
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Emactuzumab
  • Sponsor:Synox Therapeutics Limited

Study of Itolizumab with Corticosteroids for Initial Treatment of Acute Graft Versus Host Disease in Patients After Bone Marrow Transplant

Investigational
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Itolizumab
  • Sponsor:Equillium Inc.

Thymoma malignant

Not recruiting

Study of Nivolumab and Ipilimumab for Patients with Type B3 Thymoma and Thymic Carcinoma After Chemotherapy

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Ipilimumab
  • Sponsor:European Organisation For Research And Treatment Of Cancer

Pulmonary fibrosis

Not recruiting

Study of Inhaled Pirfenidone for Patients with Progressive Pulmonary Fibrosis

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Pirfenidone
  • Sponsor:Avalyn Pharma Inc.

Study of AMG 193 alone and combined with docetaxel for treatment of advanced MTAP-null solid tumors in adult patients

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:AMG 193
  • Sponsor:Amgen Inc.

Demyelination

Not recruiting

Study on the Effectiveness and Safety of Rozanolixizumab for Adults with Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOG-AD)

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Rozanolixizumab
  • Sponsor:UCB Biopharma

Other cities in Belgium

The busiest research cities in the country

All 164 cities in Belgium

Clinical research in Ottignies

What the registry says about research in the country

01 Neurology and Consciousness Disorders

Clinical research in Ottignies includes studies focused on nervous system diseases and the recovery of patients with disorders of consciousness after severe brain injury or coma. These trials are exploring whether targeted therapies can improve wakefulness, responsiveness, and overall neurological recovery.

  • Evaluation of ketamine for post-comatose patients with impaired consciousness
  • Assessment of apomorphine hydrochloride for severe brain injury and consciousness recovery
  • Study of zolpidem responses in patients with disorders of consciousness
  • Research into the mechanisms behind paradoxical neurological responses

Together, these trials aim to improve treatment options and deepen understanding of how the brain may respond to therapy in complex neurological conditions.

02 Respiratory Infections and Critical Care

Another active area of research covers respiratory tract diseases, especially severe community-acquired pneumonia and broader respiratory tract infection care in hospitalized patients. The goal is to identify better ways to support recovery and reduce serious outcomes in people admitted with acute infections.

  • Testing supportive interventions for hospitalized patients with acute respiratory tract infection
  • Evaluating treatment options for severe community-acquired pneumonia
  • Measuring effects on survival and recovery over time

This line of research is particularly relevant for intensive care settings, where timely and effective treatment can strongly influence patient outcomes.

03 Oncology and Breast Cancer

In the field of neoplasms, trials are studying advanced breast cancer with specific genetic features, including ER-positive and HER2-negative disease. Research is centered on whether new treatment combinations can improve disease control in patients with hard-to-treat cancers.

  • Testing a combination approach for selected metastatic breast cancer patients
  • Focusing on tumors with BRCA and HRR alterations
  • Assessing benefits in patients with advanced hormone-receptor-positive disease

These studies are designed to evaluate treatment effectiveness and offer more personalized options for people with genetically defined cancer subtypes.

04 Epilepsy and Rare Neurological Syndromes

Research in nervous system diseases also includes long-term treatment studies for rare epileptic disorders such as Dravet syndrome and Lennox-Gastaut syndrome. The emphasis is on improving seizure control while keeping therapy safe and tolerable over time.

  • Long-term safety evaluation of soticlestat as add-on therapy
  • Support for patients already receiving standard epilepsy care
  • Focus on chronic management of Dravet syndrome and Lennox-Gastaut syndrome

This research is important for families and clinicians seeking better options for rare and severe seizure disorders.

05 Women’s Health and Viral Infections

Within female urogenital diseases and pregnancy-related conditions, clinical trials are examining human papillomavirus infection and strategies to help clear persistent genital HPV. The main purpose is to test whether new approaches can improve infection outcomes and reduce long-term risk.

  • Comparing a candidate intervention with placebo for genital HPV clearance
  • Targeting high-risk oncogenic HPV infections
  • Supporting prevention efforts in women’s health

This area links infection control with cancer prevention, making it a meaningful focus in preventive medicine.

06 Vision Research and Physiological Responses

A smaller but distinctive research stream examines physiological processes in people with acquired partial or total vision impairments and in neurotypical volunteers. These studies aim to better understand unusual responses to treatment and how such responses may inform personalized care.

  • Studying temporary visual improvement in patients with vision impairments
  • Comparing responses in volunteers and patient groups
  • Exploring how unusual drug responses may reveal biological mechanisms

The findings may help clarify why some individuals respond differently to the same treatment and support more tailored clinical decisions.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.